The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ADXN | +2.07% | -96.54% | -48.93% | -97% |
| S&P | +13.95% | +78.35% | +12.25% | +112% |
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.
No news articles found for Addex Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $61.98K | -8.0% |
| Gross Profit | $59.33K | 977.2% |
| Gross Margin | 95.73% | 87.6% |
| Market Cap | $7.75M | -3.2% |
| Market Cap / Employee | $3.87M | 0.0% |
| Employees | 2 | 0.0% |
| Net Income | -$1,970.84K | -11.8% |
| EBITDA | -$867.26K | -32.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.75M | -30.8% |
| Accounts Receivable | $64.41K | -89.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $36.40K | -16.0% |
| Short Term Debt | $9.53K | 11.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -62.11% | 8.3% |
| Return On Invested Capital | -163.87% | 125.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$687.40K | -50.5% |
| Operating Free Cash Flow | -$687.40K | -51.0% |
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 1.88 | 1.43 | 0.76 | 0.64 | - |
| Price to Book | 0.44 | 0.46 | 0.82 | 0.97 | 70.30% |
| Price to Sales | 12.33 | 21.83 | 41.03 | 47.53 | 298.31% |
| Price to Tangible Book Value | 0.44 | 0.46 | 0.82 | 0.97 | 69.31% |
| Enterprise Value to EBITDA | -4.36 | -4.27 | -5.70 | -7.12 | 14.39% |
| Return on Equity | -92.6% | -162.4% | -61.6% | -71.3% | -16.50% |
| Total Debt | $46.34K | $45.44K | $48.22K | $45.94K | -11.46% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
